Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 | O60894 | 1/20 | 0.48 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 6/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638625 | 1.00 | RAMP1 (0.48) | RAMP1CALCRLACEMMETPSAB1 | |
| SCHEMBL4229630 | 0.88 | FPR2 (0.46) | RAMP1CALCRLACEMMEFPR2 | |
| SCHEMBL27706684 | 0.87 | RAMP1 (0.43) | RAMP1CALCRLACEMMETPSAB1 | |
| SCHEMBL5638958 | 0.83 | ACE (0.44) | ACEMMESRCF10MMP1 | |
| SCHEMBL21143944 | 0.83 | ACE (0.44) | ACEMMESRCF10MMP1 | |
| SCHEMBL10941726 | 0.83 | ACE (0.59) | ACEMMETPSAB1TPSD1TPSG1 | |
| SCHEMBL5641213 | 0.82 | SRC (0.43) | ACEMMETPSAB1TPSD1TPSG1 | |
| SCHEMBL6224777 | 0.82 | SRC (0.43) | ACEMMETPSAB1TPSD1TPSG1 | |
| SCHEMBL14170204 | 0.81 | RAMP1 (0.42) | RAMP1CALCRLACEMMETPSAB1 | |
| SCHEMBL3276179 | 0.81 | F10 (0.57) | ACEMMEF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765805-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1615914-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1765805-A4 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7491713-B2 | CGRP receptor antagonists | MERCK + CO., INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20070287696-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| US-7205292-B2 | Piperidines containing a lactam ring and a quinolinone, benzimidazolone, quinazolinone or benzodiazepinone group, e.g. N-[3R,7R)-1-(Cyclopropylmethyl)-2-oxo-7-phenylazepan-3-yl]-4-(2-oxo-1,4-dihydroquinazolin-3 (2H-yl)piperidine-1-carboxamide; treating headaches, migraine headaches and cluster headaches | MERCK & CO., INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1765805-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060194783-A1 | Cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-08-31 | — | — | US | disclosed |
| WO-2005072308-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194783-A1 | Cgrp receptor antagonists | BDKRB1, CCKBR, BDKRB2 | RAMP1 105/4885CALCRL 6/4885ACE 2305/4885 |
| US-20070287696-A1 | Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | RAMP1 120/4885CALCRL 4/4885ACE 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.